A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)

Trial Profile

A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C; HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ALLY-2
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 Feb 2016 Results published in Bristol-Myers Squibb Company media release.
    • 28 Jan 2016 According to a Bristol-Myers Squibb media release the European Commission has approved the expansion of indication for Daklinza (daclatasvir) to be used in combination with sofosbuvir, with or without ribavirin in HCV patients with decompensated cirrhosis, HIV-1 coinfection, and post-liver transplant recurrence of HCV in all 28 Member States of the European Union. The approval is based on the ALLY-1 and ALLY-2 studies.
    • 06 Oct 2015 According to a Bristol-Myers Squibb media release, the U.S. FDA has accepted for filing and review supplemental New Drug Applications (sNDAs) for Daklinza (daclatasvir), an NS5A replication complex inhibitor, for use with sofosbuvir with or without ribavirin.The new sNDAs accepted by the FDA for review include data from the ALLY-1 and ALLY-2 clinical trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top